Suitability of CD133 as a Marker for Cancer Stem Cells in Melanoma.

Philippe KornAndreas KampmannSimon SpalthoffPhilipp JehnFrank TavassolFritjof LentgeNils-Claudius GellrichRüdiger Zimmerer

Published in: Asian Pacific journal of cancer prevention : APJCP (2021)

In contrast to the results obtained in prior studies, the suitability of CD133 as a CSC marker could not be demonstrated. The current encouraging progress in targeted therapy for malignant melanoma highlights the need to identify more effective targets.

Keyphrases

cancer stem cells
magnetic resonance
cancer therapy
magnetic resonance imaging
contrast enhanced
case control